Bispecific T-Cell Engagers Improve Immune Response in Multiple Myeloma
Thomas G. Martin, MD, discusses the mechanism of action of bispecific T-cell engagers including teclistamab-cqyv in patients with relapsed/refractory multiple myeloma.
Goals and Efficacy of the MajesTEC-1 Trial in Multiple Myeloma
Thomas G. Martin, MD, discusses the goals and efficacy outcomes of the phase 1/2 MajesTEC-1 trial of teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.
Exploring CD38 Antibodies as Treatment in Multiple Myeloma
Thomas G. Martin, MD, discusses the use of anti-CD38 antibodies in patients with multiple myeloma.